FIG. 1.
Clinical response at the end of treatment and at follow-up (14 to 28 days posttreatment) for patients treated with grepafloxacin (Grepa) at 400 mg once daily (n = 151 and 143, respectively), grepafloxacin at 600 mg once daily (n = 156 and 151, respectively), or ciprofloxacin (Cip) at 500 mg twice daily (n = 160 and 154, respectively) (clinical efficacy evaluable population).